Stay in touch with ACCRF and learn about the newest advances in ACC research by signing up to receive our email updates. You can expect to receive one email update per quarter.
11.29.14 - ACCRF Update
Recent developments in clinical trials, cell lines, patient assistance and more.
Recent developments in clinical trials, cell lines, patient assistance and more.
06.09.14 - ACCRF Update
A review of the ACCRF Scientific Forum at the Salk Institute, recent clinical trial developments, NIH grant announcements and patient...
A review of the ACCRF Scientific Forum at the Salk Institute, recent clinical trial developments, NIH grant announcements and patient...
12.15.13 - ACCRF Year-End Letter
A blend of annual accomplishments, patient education resources and clinical trial developments.
A blend of annual accomplishments, patient education resources and clinical trial developments.
10.18.13 - Update for Researchers
A review of recent developments, including The Landscape of ACC Research, orphan drug designation for Dovitinib, the International MYB Conference,...
A review of recent developments, including The Landscape of ACC Research, orphan drug designation for Dovitinib, the International MYB Conference,...
06.18.13 - More on "Quiet" Genomes
Yet another seminal study of ACC genomics reveals “quiet” genomes with relatively few molecular alterations in most tumors. The implication...
Yet another seminal study of ACC genomics reveals “quiet” genomes with relatively few molecular alterations in most tumors. The implication...
05.31.13 - Genomic Findings, Clinical Trials & Patient Activities
The past few months have seen a flurry of significant research findings. A major scholarly article depicts the landscape of...
The past few months have seen a flurry of significant research findings. A major scholarly article depicts the landscape of...
12.20.12 - ACCRF Year End Letter
Highlights from a remarkable year include a third Dovitinib clinical trial, $8 million in NIH grants and a revamped website.
Highlights from a remarkable year include a third Dovitinib clinical trial, $8 million in NIH grants and a revamped website.
09.20.12 - 3rd Workshop on Salivary Gland Tumors
The re-invigoration of the field of salivary gland tumor research over the past 6 years has been a very welcome...
The re-invigoration of the field of salivary gland tumor research over the past 6 years has been a very welcome...
02.03.12 - Dovitinib Study Opens at the University of Virginia
The University of Virginia has begun screening ACC patients with progressive disease for a new clinical trial. Supported by Novartis...
The University of Virginia has begun screening ACC patients with progressive disease for a new clinical trial. Supported by Novartis...
01.09.12 - RFAs for Salivary Gland Tumor Research
The National Institute of Dental and Craniofacial Research (NIDCR) posted two Requests for Applications (RFAs) seeking grant proposals to enhance...
The National Institute of Dental and Craniofacial Research (NIDCR) posted two Requests for Applications (RFAs) seeking grant proposals to enhance...